New trial aims to give every blood cancer patient a donor

NCT ID NCT06809712

Recruiting now Disease control Sponsor: He Huang Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether stem cell transplants from donors whose tissue type does not fully match the patient can be safe and effective for people with blood cancers who have no other donor options. About 29 adults aged 18-60 will receive chemotherapy followed by the transplant. The main goal is to see how many patients survive over time, while also tracking how well the new stem cells take hold.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: allogeneic hematopoietic stem cell transplant (donor stem cells) with chemotherapy drugs (busulfan, cyclophosphamide, fludarabine, semustine)
What this could lead to: If successful, this approach could provide a transplant option for blood cancer patients who currently have no suitable donor, potentially improving survival.
What could go wrong: This is a very early phase 1 trial with only 29 participants, so results may not apply broadly. There are significant risks including graft failure, severe infection, and graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematologic disorder hematopoietic and lymphoid cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC DISEASE

Contacts and locations

Locations

The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, 310003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.